Why Do Biologics Have Such Funny Names?

If you still watch commercial television, chances are you've been lambasted with appeals to ask your doctor to prescribe you one of the new biologics coming out. The big print will feature the brand name, which is then repeated many times throughout the narrative. But the small print will give the generic name, which always seems to sound like a certain Phil Collins song.

Every year seems to bring a new parade of miracle cures, and every year the price of miracles seems to go up. I've started to refer to this trend as "Ransom-Level Pricing," because, at least in the US, the wonder drug revenue formula seems to be based on YMOYL.

I fully expect the next big med to be named after an actual rock and roll band.

What's the Rx Industry Expert Gab for 2023?

And, indeed, there is a site that blabs about all the money expected to be spent on the lab-tested snake oil in this year's pipeline. Or, if you'd rather limit your reading to a Fierce little summary, you could read an article about the drugs that will try to nab our hearts.

Or stab our kidneys. 

Or clear our minds, whatever.

But before you do even that, you might want to check out this fab decoder ring, which explains what all the suffix is about.

It's a -Mab -Mab -Mab -Mab World

Maybe the well-pharma wagon bringing just the medicine you need is coming down the street, right into your town, bearing a big shiny IV. You might even be one of the first to sign up for a jab!

 [And now, a word from our Sponsor: If you want to reach those doctors directly, check out the CarePrecise Enhanced Prescribing Clinician Fax Database™. Tell them Marty sent you.]

#aducanumab #donanemab #epcoritamab #lecanemab #mirikizumab

Hurry Up, Sunshine

Senators Chuck Grassly (R-IA) and Herb Kohl (D-WI), authors of the Physician Payments Sunshine Act, are pushing for CMS to get its final implementation rule out the door. Once the rule is published, the process of collecting data on financial transactions between doctors and industry vendors can start. Six months after CMS missed the October 1, 2011 statutory deadline, the senators expressed their displeasure with the agency's slow movement.

After missing the implementation date, CMS again missed a March 31, 2012 start date for the 1,150+ drug, device, biologics and medical supplies manufacturers to report all "transfers of value" given to physicians and teaching hospitals.

The Sunshine Act, as it is nicknamed, is designed to bring transparency to physician interactions with revenue sources that may unduly influence decisions regarding patient care. While such sources as manufacturers' payments for research are vital to healthcare technology development, patients should know when (and what for) large sums of money are attached to their doctors' treatment decisions.

Proposed implementation, published December 19, is available online.